undamentalytics Newsletter
Sign in

Rhythm Pharmaceuticals, Inc. income statement

In fiscal 2025, Rhythm Pharmaceuticals, Inc. reported revenue of $190m, up 45.8% on the year before, operating income of −$192m (a -101.2% margin) and net income of −$197m, or −$3.11 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue0000032477130190240
Cost of revenue—————129131926
Gross profit—————32268117170214
Research and development20235010990104109135238167173
Selling, general and administrative6102837466892118144195241
Operating income−26−32−78−146−137−170−179−184−266−192−201
Interest expense——————514212118
Income before tax—————−70−181−184−260−196−204
Income tax———————1001
Net income−29−34−74−141−134−70−181−185−261−197−205
Diluted EPS−$2.85−$2.83−$2.39−$3.86−$3.04−$1.40−$3.47−$3.20−$4.34−$3.11−$3.04
Diluted shares (average)10m13m31m36m44m50m52m58m61m65m67m
EBITDA−26−32−78−145−136−169−178−183−265−192—

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: ANAB vs RYTMIDYA vs RYTMPBYI vs RYTMLGND vs RYTM

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Rhythm Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Rhythm Pharmaceuticals, Inc.